Genotype-Phenotype Correlations in Alport Syndrome-A Single-Center Experience

Genes (Basel). 2024 May 7;15(5):593. doi: 10.3390/genes15050593.

Abstract

Background: Alport syndrome (AS) is a common and heterogeneous genetic kidney disease, that often leads to end-stage kidney disease (ESKD).

Methods: This is a single-center, retrospective study that included 36 adults with type IV collagen (COL4) mutations. Our main scope was to describe how genetic features influence renal survival.

Results: A total of 24 different mutations were identified, of which eight had not been previously described. Mutations affecting each of the type IV collagen α chains were equally prevalent (33.3%). Most of the patients had pathogenic variants (61.1%). Most patients had a family history of kidney disease (71%). The most prevalent clinical picture was nephritic syndrome (64%). One-third of the subjects had extrarenal manifestations, 41.6% of patients had ESKD at referral, and another 8.3% developed ESKD during follow-up. The median renal survival was 42 years (95% CI, 29.98-54.01). The COL4A4 group displayed better renal survival than the COL4A3 group (p = 0.027). Patients with missense variants had higher renal survival (p = 0.023). Hearing loss was associated with lower renal survival (p < 0.001).

Conclusions: Patients with COL4A4 variants and those with missense mutations had significantly better renal survival, whereas those with COL4A3 variants and those with hearing loss had worse prognoses.

Keywords: Alport syndrome; genotype–phenotype correlations; kidney survival; monogenic kidney diseases; type IV collagen-related disorders.

MeSH terms

  • Adult
  • Autoantigens
  • Collagen Type IV* / genetics
  • Female
  • Genetic Association Studies*
  • Humans
  • Kidney Failure, Chronic* / genetics
  • Kidney Failure, Chronic* / pathology
  • Male
  • Middle Aged
  • Mutation
  • Nephritis, Hereditary* / genetics
  • Nephritis, Hereditary* / pathology
  • Retrospective Studies

Substances

  • Collagen Type IV
  • COL4A4 protein, human
  • type IV collagen alpha3 chain
  • Autoantigens

Grants and funding

This research received no external funding.